| And as I mentioned above, (Nasdaq: CERO) has several potential breakout catalysts that could be worth taking notice of at the moment. Check these out...
#1. CERO Potential Catalyst - A Low Float Under 5Mn Shares Could Create A Volatile Environment.
According to the Yahoo Finance website, CERO has a low float.
In fact, the website reports this profile to have approximately 4.51Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If the company provides more positive company news in the first half of 2025, could it create a near term spark? -----
#2. CERO Potential Catalyst - An Analyst $11 Price Target Suggests 1,000+% Potential Upside.
Announced this week, D. Boral Capital initiated coverage of Cero Therapeutics with an $11 price target.
Citing the company’s innovative T cell engineering platform for cancer treatment, D. Boral Capital's target suggests a potential upside well over 1,000%.
CERo’s proprietary technology aims to enhance both innate and adaptive immune responses, positioning it as a leader in solid tumor therapies.
Recent FDA approvals and patent allowances further strengthen its clinical and intellectual property position, with key trial milestones anticipated in 2025. -----
#3. CERO Potential Catalyst - CERo Sees Additional Patent Application Allowances As Paramount To Success In The Market.
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236
Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families
SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) ..., announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office (USPTO), which materially expands the Company’s intellectual property portfolio.
...
Chris Ehrlich, CERo Therapeutics CEO, commented, “These additional patent application allowances are paramount to CERo’s success in the market as they demonstrate the true novelty of our design and approach in potentially killing cancer cells and treating patients. The robust range of patents that cover this technology in general, and CER-1236 in particular, are a continuation of the validation we have seen since the inception of the Company, demonstrating innovation -- and we believe – therapeutic potential. We are gratified to be receiving these allowances on the heels of the announcement of our initial trial site for our Phase 1 trial in AML and the announcement of our cleared IND to begin human trials to treat ovarian and non-small cell lung cancers.”
Read the full article here. -----
#4. CERO Potential Catalyst - CERo Receives FDA Clearance For A 2nd IND Application For Its Lead Compound, CER-1236.
CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) ..., announces that the Company has received clearance by the U.S. Food and Drug Administration (FDA) for a second Investigational New Drug (IND) application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.
CERo Chief Medical Officer Robert Sikorski, M.D., Ph.D. commented, “Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors and bring new therapeutic options to patients with ovarian and lung cancer. CER-1236 is novel: the first CAR-T cell therapy to target Tim-4L and the first with phagocytic activity programmed into a T cell. Preclinical data suggest that this dual mechanism may help overcome key resistance barriers that have hampered solid tumor CAR-T trials. The FDA’s collaborative role has been critical to maintaining development velocity and enabling us to operate two open trials in both hematologic and solid tumors. Taken together, this expansion reflects our belief in the therapeutic breadth and the commercial and partnering potential of CER-1236.”
...
Read the full article here. -----
#5. CERO Potential Catalyst - Company Highlights Suggest CERo Could Have A Game-Changing 2025 Ahead Of Itself.
CERo Therapeutics Holdings, Inc. Highlights Progress
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025
SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”)..., provides in-vest-ors with a corporate update highlighting its improved cash balance following its recent capital raise, steady progress in the initiation of its Phase 1 clinical trial of CER-1236, and a pathway toward maintaining Nasdaq listing.
CEO Chris Ehrlich commented, “We have had a very strong entry into 2025, which has greatly improved the outlook of the Company from the previous year. As announced, we completed a $5Mn financing, which gives us a current cash position of approximately $8Mn. We believe this funding will allow us to achieve numerous value-creating milestones in the coming year. In addition, we have also completed the conversion of the majority of our preferred shares into common shares, which significantly improves our cap table moving forward.
Further, we have been diligently working with FDA to complete the set-up of operations and processes needed to initiate our Phase I clinical trials of CER-1236 in AML as noted in our communications with the FDA. We have made significant progress with a leading cancer center as our initial trial site and believe we will dose our first patient in the trial during the first half of the year. In addition, we anticipate submitting our second IND to expand and explore CER-1236 into breast and lung cancers in the coming months.
Finally, we executed a 100:1 reverse st-ock split, which enabled us to better position ourselves within the market and move us toward complete Nasdaq compliance. A subsequent meeting with Nasdaq has provided us with the additional time we need and a path forward to achieve that compliance in the near term.
CERo has made measurable progress in the last two months, and we believe we are now in a favorable position to progress our business plan, as well as to provide a clear pathway toward shareholder value. We thank our team for its invaluable insight and tireless work, as well as our advisors who have been instrumental in getting us to this moment,” concluded Mr. Ehrlich.
Read the full article here. -----
(Nasdaq: CERO) Recap - Top Potential Breakout Catalysts To Keep An Eye On
#1. A Low Float Under 5Mn Shares Could Create A Volatile Environment.
#2. An Analyst $11 Price Target Suggests 1,000+% Potential Upside.
#3. CERo Sees Additional Patent Application Allowances As Paramount To Success In The Market.
#4. CERo Receives FDA Clearance For A 2nd IND Application For Its Lead Compound, CER-1236.
#5. Company Highlights Suggest CERo Could Have A Game-Changing 2025 Ahead Of Itself. -----
Coverage is officially initiated on CERo Therapeutics Holdings, Inc. (Nasdaq: CERO).
I'll be in touch again soon. Keep your eyes peeled.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/23/2025 and ending on 04/24/2025 to publicly disseminate information about (CERO:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CERO:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/cero/#details | 
Tidak ada komentar:
Posting Komentar